De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AbbVie Beheer

Beheer criteriumcontroles 1/4

De CEO AbbVie's is Robert Michael, benoemd in Jul2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 14.44M, bestaande uit 9.9% salaris en 90.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde € 17.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1 jaar en 11.8 jaar.

Belangrijke informatie

Robert Michael

Algemeen directeur

US$14.4m

Totale compensatie

Percentage CEO-salaris	9.9%
Dienstverband CEO	less than a year
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	11.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Robert Michael's beloning veranderd ten opzichte van AbbVie's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$5b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$14m	US$1m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$10m	US$1m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$12m	US$1m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$13m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$9m	US$907k	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$3m	US$554k	US$6b

Compensatie versus markt: De totale vergoeding ($USD 14.44M ) Robert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.31M ).

Compensatie versus inkomsten: De beloning van Robert is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Robert Michael (54 yo)

less than a year

Tenure

US$14,441,320

Compensatie

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 67.5m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 17.1m
Scott Reents	Executive VP & CFO	2.3yrs	US$10.19m	0.00087% € 2.7m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.011% € 34.8m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% € 10.8m
Roopal Thakkar	Executive VP of Research and Development & Chief Scientific Officer	less than a year	geen gegevens	0.00093% € 2.9m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Perry Siatis	Executive VP	2yrs	geen gegevens	0% € 0
Sanjay Narayan	Senior VP	less than a year	geen gegevens	geen gegevens
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% € 2.4m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	less than a year	geen gegevens	geen gegevens
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.8yrs	geen gegevens	0.0032% € 9.7m

1.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4AB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Gonzalez	Executive Chairman	11.8yrs	US$25.66m	0.022% € 67.5m
Robert Michael	CEO & Director	less than a year	US$14.44m	0.0056% € 17.1m
Roxanne Austin	Lead Independent Director	11.8yrs	US$388.39k	0.00065% € 2.0m
Thomas Freyman	Independent Director	4.4yrs	US$389.98k	0.0071% € 21.7m
Glenn Tilton	Independent Director	11.8yrs	US$421.58k	0.0014% € 4.3m
Edward Rapp	Independent Director	11.8yrs	US$394.98k	0.00091% € 2.8m
William H. Burnside	Independent Director	11.8yrs	US$377.48k	0% € 0
Frederick Waddell	Independent Director	11.8yrs	US$369.98k	0.00011% € 337.3k
Melody Meyer	Independent Director	7.4yrs	US$369.98k	0% € 0
Brett Hart	Independent Director	8.8yrs	US$384.98k	0% € 0
Rebecca Roberts	Independent Director	6.4yrs	US$359.98k	geen gegevens
Robert Alpern	Independent Director	11.8yrs	US$461.18k	0.000010% € 30.7k

11.8yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4AB zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

AbbVie Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Executive Chairman recently sold €11m worth of stock

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

AbbVie Announces Board Changes

AbbVie Inc. Announces Board of Directors Changes

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

Executive VP & Chief Commercial Officer recently sold €5.4m worth of stock

Recent updates

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold €11m worth of stock

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

Second quarter 2024 earnings released: EPS: US$0.77 (vs US$1.14 in 2Q 2023)

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings released: EPS: US$0.77 (vs US$0.13 in 1Q 2023)

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold €5.4m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Chairman & CEO recently sold €23m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd